<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epstein-Barr virus-associated post-transplant <z:e sem="disease" ids="C0024314" disease_type="Neoplastic Process" abbrv="">lymphoproliferative disease</z:e> (EBV-PTLD) is a life-threatening complication following allogeneic hematopoietic stem cell transplantation (HSCT) </plain></SENT>
<SENT sid="1" pm="."><plain>Monitoring of EBV DNA in high-risk patients with subsequent pre-emptive rituximab treatment is highly effective, and can prevent EBV-associated disease following HSCT </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we report a 10-year-old girl with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> who developed CD20 negative EBV-PTLD after unrelated bone marrow transplantation that was refractory to rituximab treatment </plain></SENT>
<SENT sid="3" pm="."><plain>Similar to other types of <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, the absence of CD20 antigen is likely to be characteristic of rituximab-refractory EBV-PTLD </plain></SENT>
</text></document>